247 related articles for article (PubMed ID: 33847681)
1. Dual therapy with an oral non-vitamin K antagonist and a P2Y12 inhibitor vs triple therapy with aspirin, a P2Y12 inhibitor and a vitamin K antagonist for the treatment of diabetes mellitus patients with co-existing atrial fibrillation following percutaneous coronary intervention: A meta-analysis.
Wang Q; Yang K
Medicine (Baltimore); 2021 Apr; 100(15):e25546. PubMed ID: 33847681
[TBL] [Abstract][Full Text] [Related]
2. Safety and Efficacy of Antithrombotic Strategies in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Network Meta-analysis of Randomized Controlled Trials.
Lopes RD; Hong H; Harskamp RE; Bhatt DL; Mehran R; Cannon CP; Granger CB; Verheugt FWA; Li J; Ten Berg JM; Sarafoff N; Gibson CM; Alexander JH
JAMA Cardiol; 2019 Aug; 4(8):747-755. PubMed ID: 31215979
[TBL] [Abstract][Full Text] [Related]
3. Risk of Stroke vs. Intracerebral Hemorrhage in Patients with Non-Valvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis of Randomized Controlled Trials Comparing Dual vs. Triple Antithrombotic Therapy.
Desai A; Escamilla-Ocanas C; Dilip D; Saber H; Damani R
J Stroke Cerebrovasc Dis; 2021 Apr; 30(4):105654. PubMed ID: 33578352
[TBL] [Abstract][Full Text] [Related]
4. Comparative Efficacy and Safety of P2Y12 Inhibitor Monotherapy and Dual Antiplatelet Therapy in Patients with and without Diabetes Mellitus Undergoing Percutaneous Coronary Intervention.
Feng WH; Chang YC; Lin YH; Chen HL; Chang HM; Chu CS
Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35562942
[TBL] [Abstract][Full Text] [Related]
5. NOAC-Based Sual Therapy Versus Warfarin-Based Triple Therapy After Percutaneous Coronary Intervention or Acute Coronary Syndrome in Patients With Atrial Fibrillation: A Systematic Review and Meta-Analysis.
Dahal K; Mosleh W; Almnajam M; Khaddr M; Adeel MY; Vashist A; Robinson P; Azrin M; Lee J
Cardiovasc Revasc Med; 2020 Oct; 21(10):1202-1208. PubMed ID: 32173329
[TBL] [Abstract][Full Text] [Related]
6. Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI.
Gibson CM; Mehran R; Bode C; Halperin J; Verheugt FW; Wildgoose P; Birmingham M; Ianus J; Burton P; van Eickels M; Korjian S; Daaboul Y; Lip GY; Cohen M; Husted S; Peterson ED; Fox KA
N Engl J Med; 2016 Dec; 375(25):2423-2434. PubMed ID: 27959713
[TBL] [Abstract][Full Text] [Related]
7. Antithrombotic Therapy in Patients With Atrial Fibrillation and Acute Coronary Syndrome Treated Medically or With Percutaneous Coronary Intervention or Undergoing Elective Percutaneous Coronary Intervention: Insights From the AUGUSTUS Trial.
Windecker S; Lopes RD; Massaro T; Jones-Burton C; Granger CB; Aronson R; Heizer G; Goodman SG; Darius H; Jones WS; Aschermann M; Brieger D; Cura F; Engstrøm T; Fridrich V; Halvorsen S; Huber K; Kang HJ; Leiva-Pons JL; Lewis BS; Malaga G; Meneveau N; Merkely B; Milicic D; Morais J; Potpara TS; Raev D; Sabaté M; de Waha-Thiele S; Welsh RC; Xavier D; Mehran R; Alexander JH;
Circulation; 2019 Dec; 140(23):1921-1932. PubMed ID: 31557056
[TBL] [Abstract][Full Text] [Related]
8. Revisiting the effects of omitting aspirin in combined antithrombotic therapies for atrial fibrillation and acute coronary syndromes or percutaneous coronary interventions: meta-analysis of pooled data from the PIONEER AF-PCI, RE-DUAL PCI, and AUGUSTUS trials.
Potpara TS; Mujovic N; Proietti M; Dagres N; Hindricks G; Collet JP; Valgimigli M; Heidbuchel H; Lip GYH
Europace; 2020 Jan; 22(1):33-46. PubMed ID: 31603196
[TBL] [Abstract][Full Text] [Related]
9. The Cost of Breaking Even: a Perspective on the Net Clinical Impact of Adding Aspirin to Antithrombotic Therapies in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention.
Triska J; Haddadin F; Madanat L; Jabri A; Daher M; Birnbaum Y; Jneid H
Cardiovasc Drugs Ther; 2024 Jun; 38(3):605-619. PubMed ID: 35829979
[TBL] [Abstract][Full Text] [Related]
10. Dual Versus Triple Therapy for Atrial Fibrillation After Percutaneous Coronary Intervention: A Systematic Review and Meta-analysis.
Khan SU; Osman M; Khan MU; Khan MS; Zhao D; Mamas MA; Savji N; Al-Abdouh A; Hasan RK; Michos ED
Ann Intern Med; 2020 Apr; 172(7):474-483. PubMed ID: 32176890
[TBL] [Abstract][Full Text] [Related]
11. Ticagrelor monotherapy after a short course of dual antiplatelet therapy with ticagrelor plus aspirin following percutaneous coronary intervention in patients with versus without diabetes mellitus: a meta-analysis of randomized trials.
Ning C; Ling F; Liu D; Zhi Z
BMC Cardiovasc Disord; 2024 Mar; 24(1):166. PubMed ID: 38504170
[TBL] [Abstract][Full Text] [Related]
12. Apixaban or Vitamin K Antagonists and Aspirin or Placebo According to Kidney Function in Patients With Atrial Fibrillation After Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From the AUGUSTUS Trial.
Hijazi Z; Alexander JH; Li Z; Wojdyla DM; Mehran R; Granger CB; Parkhomenko A; Bahit MC; Windecker S; Aronson R; Berwanger O; Halvorsen S; de Waha-Thiele S; Sinnaeve P; Darius H; Storey RF; Lopes RD
Circulation; 2021 Mar; 143(12):1215-1223. PubMed ID: 33461308
[TBL] [Abstract][Full Text] [Related]
13. Meta-Analysis Comparing Potent Oral P2Y
Casula M; Fortuni F; Ferlini M; Fabris F; Oltrona Visconti L; Leonardi S
Am J Cardiovasc Drugs; 2021 Mar; 21(2):231-240. PubMed ID: 32895853
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy outcomes of double vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials.
Gargiulo G; Goette A; Tijssen J; Eckardt L; Lewalter T; Vranckx P; Valgimigli M
Eur Heart J; 2019 Dec; 40(46):3757-3767. PubMed ID: 31651946
[TBL] [Abstract][Full Text] [Related]
15. Discontinuing Aspirin After Short Term Use Versus Continuous Use with a P2Y12 Inhibitor for the Treatment of Patients with Type 2 Diabetes Mellitus Following Percutaneous Coronary Intervention: A Meta-analysis.
Wang Q; Yang K; Bundhun PK
Diabetes Ther; 2020 Oct; 11(10):2299-2311. PubMed ID: 32844374
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of double vs. triple antithrombotic therapy in patients with atrial fibrillation with or without acute coronary syndrome undergoing percutaneous coronary intervention: a collaborative meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials.
Gargiulo G; Cannon CP; Gibson CM; Goette A; Lopes RD; Oldgren J; Korjian S; Windecker S; Esposito G; Vranckx P; Valgimigli M
Eur Heart J Cardiovasc Pharmacother; 2021 Apr; 7(FI1):f50-f60. PubMed ID: 33119069
[TBL] [Abstract][Full Text] [Related]
17. Non-vitamin K antagonist oral anticoagulants (NOACs) post-percutaneous coronary intervention: a network meta-analysis.
Al Said S; Alabed S; Kaier K; Tan AR; Bode C; Meerpohl JJ; Duerschmied D
Cochrane Database Syst Rev; 2019 Dec; 12(12):CD013252. PubMed ID: 31858590
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of non-vitamin K oral anticoagulant for atrial fibrillation patients after percutaneous coronary intervention: A bivariate analysis of the PIONEER AF-PCI and RE-DUAL PCI trial.
Chi G; Kerneis M; Kalayci A; Liu Y; Mehran R; Bode C; Halperin JL; Verheugt FWA; Wildgoose P; van Eickels M; Lip GYH; Cohen M; Peterson ED; Fox KAA; Gibson CM
Am Heart J; 2018 Sep; 203():17-24. PubMed ID: 30015064
[TBL] [Abstract][Full Text] [Related]
19. Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation.
Lopes RD; Heizer G; Aronson R; Vora AN; Massaro T; Mehran R; Goodman SG; Windecker S; Darius H; Li J; Averkov O; Bahit MC; Berwanger O; Budaj A; Hijazi Z; Parkhomenko A; Sinnaeve P; Storey RF; Thiele H; Vinereanu D; Granger CB; Alexander JH;
N Engl J Med; 2019 Apr; 380(16):1509-1524. PubMed ID: 30883055
[TBL] [Abstract][Full Text] [Related]
20. Optimisation of oral anticoagulants for patients with atrial fibrillation within 12 months after percutaneous coronary intervention: A
Wang S; Liu Y; Wang L; Zuo H; Tian Y; Wang Y; Yin D; Zhang H; Tian Y
Int J Cardiol Heart Vasc; 2021 Oct; 36():100850. PubMed ID: 34401468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
